Saturday 17 October 2026 Export EVGN’s income statement to Excel — free account

Evogene Ltd.

In the quarter to June 2026, revenue fell 35.0%, EPS grew 77.4% and free cash flow grew 17.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

0.39 0.01 −2.50%

Follow EVGN

Alert me

Market cap: $6.3M
P/E: 0.0×
Fwd P/E: 0.0×
Dividend yield: —
F-score: 4/9
Altman Z: −20.48
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.69

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	1	—	2	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 18.36%

Capital & Financial Ratios $m

Market Cap 6.32

Revenue 1.66

Net Income (16.58)

Free Cash Flow (10.78)

Net Debt (9.35)

Current Ratio 3.57

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E 0.00

P/S ratio 2.87

P/B ratio 0.82

Past 5Y EPS Growth —

This Y EPS Growth (2.08%)

Next Y EPS Growth 45.45%

Next Y revenue growth (62.73%)

Next 5Y EPS Growth 25.25%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 13.45%

10-year low 10-year high

P/B against its own 10 years 30.08%

10-year low 10-year high

EV/FCF against its own 10 years 63.95%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	31	15	13	9
Receivables	3	3	2	1
Inventory	0	2	0	0
Other	—	—	—	—
	34	22	16	11

	2023	2024	2025	Q'26
Payables	2	1	1	0
ST’ Debt	—	—	—	—
Other	0	14	1	1
	7	19	3	3

Compound Annual Growth %

	10y	5y	3y
Sales	(10.06%)	29.94%	32.01%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(19.42%)	(26.77%)	(29.92%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	2	1	0	1	4
’24	4	1	2	—	6
’23	1	1	4	1	6
’22	0	0	0	1	2
’21	0	0	0	0	1
’20	0	0	0	0	1

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(5)	(2)	(3)	(3)	(14)
’24	(4)	(5)	(6)	(5)	(20)
’23	(6)	(5)	(4)	(6)	(22)
’22	(8)	(7)	(7)	(2)	(24)
’21	(5)	(6)	(6)	(8)	(25)
’20	(5)	(3)	(4)	(7)	(20)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(5)	(2)	(3)	(3)	(14)
’24	(4)	(5)	(6)	(5)	(20)
’23	(7)	(5)	(5)	(6)	(22)
’22	(8)	(7)	(7)	(2)	(25)
’21	(5)	(6)	(6)	(8)	(26)
’20	(6)	(3)	(5)	(7)	(20)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.60)	(0.14)	—	—	—
’25	(0.38)	(0.62)	0.44	(0.61)	(1.08)
’24	(0.80)	(1.06)	(1.31)	0.06	(2.89)
’23	(1.50)	(1.70)	(0.80)	(1.30)	(5.20)
’22	(2.00)	(2.10)	(1.60)	(0.70)	(6.50)
’21	(1.70)	(1.50)	(1.90)	(1.80)	(6.90)
’20	(2.40)	(1.60)	(1.70)	(2.50)	(8.30)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	50.50	26.60	19.80	12.60	7.50	16.00	6.00	4.50	1.20	0.93	Analyst estimates 2026–2028 Powerpack
	High	85.00	58.40	42.00	26.50	60.00	102.40	19.00	14.40	10.40	2.42
People
People	Employees	240	205	171	143	131	141	137	142	117	52
	Revenue/emp, $m	0.03	0.02	0.01	0.01	0.01	0.01	0.01	0.04	0.05	0.07
Income, $m
Income, $m	Revenue	7	3	2	1	1	1	2	6	6	4
	Gross margin, %	13.78	15.85	16.89	55.64	44.81	17.53	45.73	70.00	57.32	(6.25)
	EBT	(20)	(21)	(21)	(19)	(26)	(30)	(30)	(26)	(15)	(13)
	EBT margin, %	(299.02)	(616.00)	(1,189.58)	(2,535.33)	(2,516.73)	(3,272.26)	(1,776.36)	(460.76)	(265.52)	(350.32)
	Net income	(20)	(21)	(21)	(19)	(26)	(30)	(30)	(26)	(15)	(13)
	Depreciation	2	2	2	3	3	2	3	3	2	2
Per share, $
Per share, $	Revenue	2.57	1.32	0.68	0.29	0.37	0.23	0.41	1.23	0.98	0.49
	Earnings	(7.70)	(8.10)	(8.10)	(7.00)	(8.30)	(6.90)	(6.50)	(5.20)	(2.89)	(1.08)
	Cash flow	(4.60)	(6.20)	(5.89)	(6.86)	(6.93)	(6.11)	(5.75)	(4.70)	(3.46)	(1.71)
	Capex	(0.32)	(0.23)	(0.15)	(0.35)	(0.24)	(0.21)	(0.28)	(0.17)	(0.11)	(0.01)
	Free cash flow	(4.91)	(6.43)	(6.03)	(7.21)	(7.17)	(6.32)	(6.03)	(4.87)	(3.57)	(1.72)
	Book value	34.31	27.02	19.53	23.38	20.20	15.69	8.44	6.25	2.60	1.52
	Shares, m	3	3	3	3	3	4	4	5	6	8
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	19.76	26.35	29.19	51.99	127.26	71.30	17.96	7.08	1.91	2.25
	P/B	1.48	1.28	1.01	0.65	2.33	1.05	0.86	1.39	0.72	0.72
	EV/Sales	6.28	5.13	(1.99)	(10.27)	80.88	13.38	(3.15)	1.57	(0.84)	(1.12)
	EV/FCF	(3.29)	(1.05)	0.42	0.42	(4.17)	(0.49)	0.21	(0.40)	0.23	0.32
Cash, $m
Cash, $m	Operating cash flow	(12)	(16)	(15)	(18)	(20)	(25)	(24)	(22)	(20)	(14)
	Capex	(1)	(1)	0	(1)	(1)	(1)	(1)	(1)	(1)	0
	Free cash flow	(12)	(17)	(16)	(19)	(20)	(26)	(25)	(22)	(20)	(14)
Balance, $m
Balance, $m	Working capital	84	68	50	43	42	50	32	28	3	12
	Total debt	—	—	—	1	1	1	1	—	—	—
	Net debt	(88)	(72)	(54)	(47)	(48)	(54)	(35)	(31)	(15)	(13)
	Shareholders’ equity	87	69	50	60	57	63	35	29	15	12
Returns, %
Returns, %	ROA	(18.79)	(24.01)	(30.46)	(27.85)	(32.63)	(37.50)	(40.23)	(44.54)	(36.24)	(28.33)
	ROIC	0.00	0.00	0.00	(99.16)	(179.23)	(202.49)	0.00	0.00	0.00	0.00
	ROE	(20.51)	(26.60)	(34.69)	(32.78)	(39.92)	(46.21)	(54.25)	(75.24)	(75.75)	(63.29)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
FBLG FibroBiologics Inc.	$6.7M	— (loss-making)	—	—	n/m	+21.59% (above 0%: growing)	—	0.00%	Compare
ACXP Acurx Pharmaceuticals, Inc.	$6.5M	— (loss-making)	—	—	n/m	−2.36% (below 0%: shrinking)	—	0.00%	Compare
TCRT Alaunos Therapeutics, Inc.	$6.4M	— (loss-making)	— (loss-making)	+200.00% (above 0%: growing)	n/m	+57.20% (above 0%: growing)	100.00%	0.00%	Compare
EVGN Evogene Ltd.	$6.3M	— (loss-making)	— (loss-making)	−35.02% (below 0%: shrinking)	n/m	+17.72% (above 0%: growing)	40.63%	(738.62%)
LEXX Lexaria Bioscience Corp.	$6.3M	— (loss-making)	— (loss-making)	−89.12% (below 0%: shrinking)	n/m	+53.90% (above 0%: growing)	100.00%	0.00%	Compare
ENVB Enveric Biosciences, Inc.	$6.2M	— (loss-making)	— (loss-making)	−7.28% (below 0%: shrinking)	n/m	−29.34% (below 0%: shrinking)	0.00%	0.00%	Compare
TRAW Traws Pharma, Inc.	$6.2M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−25.51% (below 0%: shrinking)	0.00%	0.00%	Compare
ALZN Alzamend Neuro, Inc.	$6.2M	— (loss-making)	—	—	n/m	+51.82% (above 0%: growing)	0.00%	0.00%	Compare
NRSN NeuroSense Therapeutics Ltd.	$6.0M	— (loss-making)	—	—	n/m	−23,458.82% (below 0%: shrinking)	—	0.00%	Compare
Median of peers	$6.3M	—	—	−48.20%	—	+9.62%	0.00%	0.00%

All 614 Biotechnology stocks →

Evogene Ltd. (EVGN) key facts

Evogene Ltd. (EVGN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, EVGN traded at $0.39, a market capitalization of $6.3 million.
Return on equity was −63.3% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −20.48 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.